Mepolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL-5 |
| Clinical data | |
| Trade names | Nucala |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615058 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% (estimate) |
| Protein binding | None |
| Metabolism | Proteolytic enzymes |
| Elimination half-life | 20 (16–22) days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 149 kDa |
| (what is this?) (verify) | |
Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES).[5] It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.
The most common side effects include headache, injection site reactions, and back pain.[4]
- ^ "Mepolizumab (Nucala) Use During Pregnancy". Drugs.com. 14 June 2019. Retrieved 8 October 2020.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
- ^ a b Cite error: The named reference
Nucala EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
FDA PR 20200925was invoked but never defined (see the help page).